HPV Vaccine Communication Strategies for Adolescent Vaccine Uptake
Trial Summary
What is the purpose of this trial?
The safe, highly-effective human papillomavirus (HPV) vaccine remains underused in the US; only 51% of 13- to 17-year-old girls and boys were up-to-date by 2018. The Announcement Approach Training is effective in increasing HPV vaccine uptake during the clinic visit by training providers to make strong vaccine recommendations and answer parents' common questions. Systems communication like recall notifications also improve vaccination by reducing missed clinical opportunities. Although never tested to support HPV vaccination, the ECHO (Extension for Community Healthcare Outcomes) Model is a proven implementation strategy to promote capacity exchange between health care experts at academic centers and primary care providers at the front line of rural community health care. The trial will test the effectiveness of two ECHO-delivered HPV vaccination communication interventions versus control: HPV ECHO will provide Announcement Approach training, and HPV ECHO+ will provide training plus recall notices to communicate with parents who initially decline vaccination.
Research Team
William A Calo, PhD, JD, MPH
Principal Investigator
Penn State College of Medicine
Eligibility Criteria
This trial is for family medicine or pediatric clinics in Pennsylvania with at least 100 active patients aged 11-14. It's also for parents or guardians of adolescents aged 11-17 who have not started the HPV vaccine and receive care at participating clinics. Clinics outside PA, those involved in recent HPV research, or patients already vaccinated are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Clinics receive HPV ECHO training via videoconferencing, focusing on the Announcement Approach over 10 sessions
Follow-up
Participants are monitored for changes in HPV vaccination rates among 11- to 17-year-olds
Treatment Details
Interventions
- Announcement Approach Training
- HPV Vaccine
- Project ECHO
- Recall notices
HPV Vaccine is already approved in United States, European Union, Canada, Switzerland for the following indications:
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
Find a Clinic Near You
Who Is Running the Clinical Trial?
Milton S. Hershey Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator